| __timestamp | Apellis Pharmaceuticals, Inc. | Supernus Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2908166 | 72471000 |
| Thursday, January 1, 2015 | 6356782 | 89204000 |
| Friday, January 1, 2016 | 4303743 | 106010000 |
| Sunday, January 1, 2017 | 10463151 | 137905000 |
| Monday, January 1, 2018 | 22639184 | 159888000 |
| Tuesday, January 1, 2019 | 67046483 | 158425000 |
| Wednesday, January 1, 2020 | 139401000 | 200677000 |
| Friday, January 1, 2021 | 176771000 | 304759000 |
| Saturday, January 1, 2022 | 277163000 | 377221000 |
| Sunday, January 1, 2023 | 500815000 | 336361000 |
Unveiling the hidden dimensions of data
In the competitive landscape of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. From 2014 to 2023, Apellis Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc. have shown distinct strategies in handling these costs. Apellis started with a modest $2.9 million in 2014, but by 2023, their SG&A expenses surged to $500 million, reflecting a strategic expansion and investment in growth. In contrast, Supernus maintained a more consistent trajectory, peaking at $377 million in 2022 before slightly reducing to $336 million in 2023. This indicates a more controlled approach to cost management. Over the decade, Apellis's SG&A expenses grew by an astonishing 17,000%, while Supernus saw a 364% increase. These figures highlight the contrasting financial strategies of these two companies, offering insights into their operational priorities and market positioning.
Cost Management Insights: SG&A Expenses for Takeda Pharmaceutical Company Limited and Supernus Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Catalent, Inc. or Apellis Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Madrigal Pharmaceuticals, Inc. or Supernus Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Corcept Therapeutics Incorporated and Supernus Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? TG Therapeutics, Inc. or Supernus Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for ADMA Biologics, Inc. and Apellis Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: CymaBay Therapeutics, Inc. vs Supernus Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Apellis Pharmaceuticals, Inc. or Viking Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Apellis Pharmaceuticals, Inc. and Mesoblast Limited
Apellis Pharmaceuticals, Inc. or Travere Therapeutics, Inc.: Who Manages SG&A Costs Better?
Ligand Pharmaceuticals Incorporated and Supernus Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Supernus Pharmaceuticals, Inc. vs Galapagos NV Trends and Insights